From 1 November, the Government will invest more than $86 million over the next four years to provide greater access to life saving medicines for Australians living with Multiple Sclerosis (MS), and various forms of cancer.
MS is the most commonly acquired neurological disease in younger adults with over 25,600 Australians living with multiple sclerosis and over 2.3 million people affected globally.
The average age of diagnosis is only 30 and around 75% of those affected with multiple sclerosis in Australia are female.
There is a high clinical need for effective treatments for patients with progressive forms of relapse onset multiple sclerosis.
Mayzent® (siponimod) will be listed on the PBS for the first time to treat those patients with secondary progressive multiple sclerosis.
Without PBS subsidy, these patients would pay more than $25,000 per year for treatment with approximately 800 patients benefiting from this listing each year.
The PBS subsidy now means patients will only need to pay $41 per prescription, or $6.60 with a concession card.
In addition to this listing, Australians diagnosed with a rare type of lymphoma which affects the skin will receive subsidised access to a new medication and specialised treatment from 1 November 2020 through an investment of over $11.5 million.
Cutaneous T-cell lymphoma is a type of non-Hodgkin lymphoma that affects the skin and causes an accumulation of malignant T-cells in the skin, resulting in raised, rash-like or itchy patches of skin, skin lumps or ulcers and swollen lymph nodes.
Uvadex® (methoxsalen) will be listed on the PBS for the first time for treatment of patients with erythrodermic cutaneous T-cell lymphoma who have not responded to other treatments.
Around 75 patients per year may benefit from this listing. Without PBS subsidy, these Australians would pay more than $3,400 per year.
Concurrently, two new items will be introduced on the Medicare Benefits Schedule (MBS) for the use of extracorporeal photopheresis (ECP) in combination with Uvadex® to treat the condition, as recommended by the Medical Services Advisory Committee.
ECP is a type of treatment that involves attaching a patient to a machine that removes some of their blood. The machine separates the white blood cells, and the red blood cells and plasma go back into the body. The white blood cells are mixed with Uvadex®, exposed to ultraviolet (UV) light, then put back into the patient. ECP activates the patient’s immune system to fight the cancer.
Other PBS listings from 1 November – announced in the Budget 2020-21 – include the expanded listing of:
· Tecentriq® and Avastin® (atezolizumab and bevacizumab) for use in combination to treat patients with advanced unresectable hepatocellular carcinoma, the most common type of primary liver cancer. An average of 500 patients per year may benefit from this. They would normally pay up to $170,000 for a course of treatment without PBS subsidy
· Lynparza® (olaparib) for the treatment of newly diagnosed advanced high grade epithelial ovarian, fallopian tube or primary peritoneal cancers. An average of 300 patients per year may benefit from this listing and would normally pay around $140,500 per course of treatment for this medicine.
These PBS listings have been recommended by the independent Pharmaceutical Benefits Advisory Committee.
Since 2013, the Australian Government has approved over 2,450 new or amended listings on the PBS.
This represents an average of around 30 listings or amendments per month – or one each day – at an overall investment by the Government of $11.8 billion.
The Government’s commitment to ensuring that Australians can access affordable medicines, when they need them, remains rock solid.